

**LEGISLATIVE FISCAL OFFICE**  
**Fiscal Note**



Fiscal Note On: **HB 761** HLS 26RS 987

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

<b>Date:</b> April 15, 2026	9:22 AM	<b>Author:</b> HILFERTY
<b>Dept./Agy.:</b> Insurance/Health		<b>Analyst:</b> John McKay
<b>Subject:</b> Increases the Rare Cancer Advisory Board's Membership		

HEALTH/CANCER

RE NO IMPACT See Note

Page 1 of 1

Provides with respect to the advisory board created to recommend new treatments for rare cancers

Proposed legislation increases the membership of the Rare Cancer Advisory Board from 15 to 17 members by expanding the number of oncologists specializing in rare cancer treatment from two to four. Proposed law extends the timeframe for the Rare Cancer Advisory Board to compile and submit its findings from 30 to 45 days following each quarterly public meeting and requires that these findings be submitted as a formal written report to the House and Senate Committees on Insurance.

EXPENDITURES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Local Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
<b>Annual Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

  

REVENUES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Local Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
<b>Annual Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

**EXPENDITURE EXPLANATION**

There is no anticipated direct material effect on governmental expenditures as a result of this measure. The Louisiana Department of Insurance (LDI) does not anticipate an expenditure impact as a result of the proposed legislation which increases the membership of the Rare Cancer Advisory Board from 15 to 17 members by expanding the number of oncologists specializing in rare cancer treatment from two to four, extends the timeframe for the board to compile and submit its findings from 30 to 45 days following each quarterly public meeting, and requires that these findings be submitted as a formal written report to the House and Senate Committees on Insurance.

**REVENUE EXPLANATION**

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate

Dual Referral Rules

House

13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}

6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}

13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

**Patrice Thomas**  
**Deputy Fiscal Officer**